Core Viewpoint - The report highlights the increasing accounts receivable among A-share pharmaceutical companies, with a significant number exceeding 10 billion yuan, indicating potential liquidity issues and financial health concerns in the industry [1][3]. Accounts Receivable Overview - As of the end of Q3, 14 A-share pharmaceutical companies reported accounts receivable exceeding 10 billion yuan, with Shanghai Pharmaceuticals leading at 88.783 billion yuan, followed by Jiuzhoutong at 39.09 billion yuan [3][4]. - The blood products sector has seen a notable increase in accounts receivable, with companies like Tiantan Biological and Boya Biological reporting significant year-on-year growth [5][6]. Industry Characteristics - The pharmaceutical distribution sector is primarily responsible for high accounts receivable, as public hospitals, which dominate the market, often negotiate longer payment terms, leading to increased receivables for distributors [3][10]. - Companies may adopt lenient credit policies to attract more clients, which can temporarily boost sales but also result in higher accounts receivable [3][10]. Financial Ratios - Eight companies have accounts receivable constituting over 50% of their total assets, with Renmin Tongtai having the highest ratio at 62.1% [8][9]. - *ST Suwu and Zhongyao Holdings follow, with accounts receivable ratios of 56.28% and significant increases compared to the previous year [9][10]. Performance Implications - High accounts receivable can lead to reduced cash flow and increased opportunity costs, potentially impacting profitability due to higher bad debt provisions [10]. - However, in certain scenarios, elevated accounts receivable may not be detrimental if they align with healthy revenue and profit growth, and if customer quality and payment terms are managed effectively [10].

Market Overview - The biopharmaceutical sector increased by 0.7% on October 29, with C禾元 leading the gains [1] - The Shanghai Composite Index closed at 4016.33, up 0.7%, while the Shenzhen Component Index closed at 13691.38, up 1.95% [1] Top Gainers in Biopharmaceutical Sector - C禾元 (688765) closed at 113.22, with a significant increase of 24.28% and a trading volume of 208,800 shares, amounting to 2.171 billion yuan [1] - 奥浦迈 (688293) closed at 62.11, rising by 9.97% with a trading volume of 24,900 shares, totaling 149 million yuan [1] - 吴帆生物 (301393) closed at 54.59, up 5.06% with a trading volume of 45,800 shares, amounting to 244 million yuan [1] Other Notable Performers - 诺思兰德 (920047) closed at 25.93, increasing by 4.09% with a trading volume of 52,000 shares, totaling 130 million yuan [1] - 沃森生物 (300142) closed at 11.78, up 3.79% with a trading volume of 521,600 shares, amounting to 614 million yuan [1] - 三生国健 (688336) closed at 61.72, increasing by 3.52% with a trading volume of 86,900 shares, totaling 526 million yuan [1] Decliners in Biopharmaceutical Sector - 百奧泰 (688177) closed at 26.70, down 2.52% with a trading volume of 21,700 shares, totaling 57.768 million yuan [2] - 派林生物 (000403) closed at 15.73, decreasing by 2.30% with a trading volume of 159,000 shares, amounting to 251 million yuan [2] - 康华生物 (300841) closed at 74.59, down 2.06% with a trading volume of 27,800 shares, totaling 208 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 399 million yuan from institutional investors, while retail investors saw a net inflow of 331 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2][3] Individual Stock Capital Flow - 辽宁成大 (600739) had a net inflow of 38.8721 million yuan from institutional investors, while retail investors had a net outflow of 15.3175 million yuan [3] - C禾元 (688765) saw a net inflow of 36.5446 million yuan from institutional investors, with retail investors experiencing a net outflow of 62.1427 million yuan [3] - 康弘药业 (002773) had a net inflow of 19.6335 million yuan from institutional investors, while retail investors faced a net outflow of 26.8166 million yuan [3]

Core Viewpoint - The company has decided to terminate the development of prothrombin complex concentrate and shift focus to the more advantageous development of human coagulation factor IX, due to market demand, competitive landscape, and cost-effectiveness considerations [1][2]. Market Demand and Competitive Landscape - The domestic market for prothrombin complex concentrate has seen stable issuance volumes with limited new market space, while the market for human factor IX has fewer competitors and significant growth potential [1]. - Human factor IX is considered a better option for treating hemophilia B due to its lower risk of thrombotic side effects compared to prothrombin complex concentrate [1][2]. Product Comparison Analysis - Prothrombin complex concentrate contains various vitamin K-dependent factors and may pose risks of thrombosis with repeated high-dose use, while human factor IX is purer and has a higher specific activity, making it a safer treatment option [1][2]. Cost-Effectiveness Analysis - The clinical trial approval for prothrombin complex concentrate was obtained in 2008, but the regulatory requirements for production site changes and the need for extensive research have made it less economically viable compared to human factor IX, which has a higher sales price and greater market growth potential [2][4]. Project Background and Investment Plan - The genomic DNA length of human factor IX is approximately 34,000 bp, and the project is expected to complete development and obtain production approval by the end of 2030 [2][4]. - The estimated investment for the development of human factor IX is 60 million yuan, with funding sourced from both raised capital and the company's own funds [4]. Project Benefits and Feasibility - The human factor IX product is aimed at treating patients with factor IX deficiency (hemophilia B), and the limited number of competitors in this market suggests significant future growth opportunities [5]. - The project aligns with market trends and the company's operational needs, enhancing resource allocation and economic benefits, thereby improving profitability and market competitiveness [5][7]. Implementation Timeline - The implementation timeline for the new product development is expected to be completed by the end of 2030, with the associated production line construction already finished [6][4]. Impact of Changes on the Company - The termination of the prothrombin complex concentrate project will reduce the current year's net profit but is expected to enhance the company's future product development and sales capabilities [7]. - The board and supervisory committee have approved the change in fundraising purposes, emphasizing the alignment with the company's operational needs and long-term interests [8][10].

Core Viewpoint - The company has announced changes regarding its financial reporting and the use of raised funds, including the appointment of new auditors and the reallocation of surplus funds to enhance operational efficiency [6][34][46]. Financial Reporting - The board and management have confirmed the accuracy and completeness of the quarterly report, which has not been audited [2][3]. - The company has not made any retrospective adjustments or restatements to previous accounting data [3]. Auditor Changes - The company has appointed new signing auditors from KPMG Huazhen due to internal adjustments, with the new auditors being Wang Pu and Li Bingman [6][7]. Shareholder Meeting - The company will hold its third extraordinary general meeting on November 13, 2025, to discuss various proposals, including the reallocation of surplus funds [12][13][14]. Fund Utilization - The company plans to permanently supplement its working capital with surplus funds from completed projects, totaling approximately 27.62 million yuan [34][39]. - The surplus funds are primarily due to lower-than-expected transaction costs and effective cash management [37][38]. Project Changes - The company has revised the use of raised funds for new product development, shifting focus from the development of prothrombin complex to factor IX, while maintaining the overall budget for the project at 340.5 million yuan [46][47].

Group 1 - The company Palin Bio announced the convening of its 18th temporary board meeting on October 27, 2025, via communication methods to review the Q3 2025 report and other documents [1] - For the first half of 2025, the company's revenue composition was 99.95% from the pharmaceutical industry and 0.05% from other businesses [1] Group 2 - As of the report, the market capitalization of Palin Bio is 15.3 billion yuan [2]

关于变更签字注册会计师的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司"）分别于2025年8月20日、2025 年9月8日召开了第十届董事会第十七次会议和2025年第二次临时股东大会，审议通 过了《关于公司2025年度续聘审计机构的议案》，同意续聘毕马威华振会计师事务所 （特殊普通合伙）（以下简称"毕马威华振"）为本公司2025年度财务报告和内部控 制审计机构，具体内容详见公司于2025年8月22日在《证券时报》《上海证券报》和 巨潮资讯网（www.cninfo.com.cn）上披露的《关于2025年度续聘审计机构的公告》 （公告编号：2025-038）。 证券代码：000403 证券简称：派林生物 公告编号：2025-050 派斯双林生物制药股份有限公司 员。李炳曼女士于2022年开始为本公司提供审计服务，任公司审计服务项目经理职 务，近三年未签署或复核上市公司审计报告。 2、 独立性和诚信情况 李炳曼女士近三年不存在因执业行为受到刑事处罚，受到证监会及其派出机构、 行业主管部门的行政处罚、监督管理措施， ...

关于部分募投项目节余募集资金永久补充流动资金的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司""上市公司"）于 2025 年 10 月 27 日召开第十届董事会第十八次会议及第十届监事会第十二次会议审议通 过《关于部分募投项目节余募集资金永久补充流动资金的议案》。鉴于公司募集资 金投资项目"单采血浆站新建及迁建项目""信息化建设项目""补充上市公司及标 的公司流动资金、偿还债务""支付相关中介机构费用"均已投入及实施完成。根 据公司经营发展需要，为提高募集资金的使用效率，拟将部分募投项目节余募集资 金用于永久补充流动资金。 根据《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指引 第 1 号——主板上市公司规范运作》等有关规定，该事项需提交公司股东大会审议 通过后方可实施。现将有关情况公告如下： 一、公司募集资金的基本情况 经中国证券监督管理委员会《关于核准南方双林生物制药股份有限公司向哈尔 滨同智成科技开发有限公司等发行股份购买资产并募集配套资金的批复》（证监许 可【2020】3412号），同 ...

证券代码：000403 证券简称：派林生物 公告编号：2025-047 派斯双林生物制药股份有限公司 关于变更募集资金用途的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召 开第十届董事会第十八次会议和第十届监事会第十二次会议审议通过了《关于变更 募集资金用途的议案》，根据公司全资子公司哈尔滨派斯菲科生物制药有限公司（以 下简称"派斯菲科"）实际经营需要及未来发展规划，结合血液制品市场需求、竞 争格局以及成本效益等因素综合评估，为进一步提高募集资金使用效率，合理配置 公司资源，聚焦更具发展潜力的研发项目，董事会同意公司变更新产品研发及配套 生产线建设项目募集资金用途，具体情况如下： 一、变更募集资金用途的概述 （一）募集资金使用基本情况 经中国证券监督管理委员会《关于核准南方双林生物制药股份有限公司向哈尔 滨同智成科技开发有限公司等发行股份购买资产并募集配套资金的批复》（证监许 可【2020】3412号），同意公司向特定对象非公开发行人民币普通股（A股）191,595 ...

证券代码：000403 证券简称：派林生物 公告编号：2025-049 派斯双林生物制药股份有限公司 关于召开2025年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议基本情况 1、股东大会届次：2025 年第三次临时股东大会 2、股东大会召集人：公司董事会，本次股东大会经公司第十届董事会第十八次 会议（临时会议）决议召开。 3、会议召开的合法、合规性：本次会议的召集和召开符合《中华人民共和国公 司法》《派斯双林生物制药股份有限公司章程》的有关规定，合法有效。 4、会议召开时间： 现场会议时间：2025 年 11 月 13 日（星期四）15:00 网络投票时间：其中，通过深圳证券交易所交易系统网络投票的时间为：2025 年 11 月 13 日上午 9:15—9:25；9:30—11:30，下午 13:00—15:00；通过深圳证券交易 所互联网投票系统网络投票时间为：2025 年 11 月 13 日上午 9:15 至下午 15:00 期间 的任意时间。 5、会议召开方式：会议采取现场投票与网络投票相结合方式召开。 公司将通 ...

证券代码：000403 证券简称：派林生物 公告编号：2025-046 派斯双林生物制药股份有限公司 第十届监事会第十二次会议（临时会议）决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 派斯双林生物制药股份有限公司（以下简称"公司"）第十届监事会第十二次会议 （临时会议）于2025年10月27日以通讯方式召开，会议由公司监事会主席郭麾先生召集 并主持。本次会议通知于2025年10月24日以通讯方式发出，会议应出席监事5人，实际 出席监事5人，会议程序符合《公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 与会监事经过认真讨论，审议了以下议案： 1、《2025 年第三季度报告》 经审核，监事会认为董事会编制和审议公司2025年第三季度报告的程序符合法律、 行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了上市公司的实际情 况，不存在任何虚假记载、误导性陈述或者重大遗漏。具体内容详见《派斯双林生物制 药股份有限公司2025年第三季度报告》，于同日刊登在《证券时报》《上海证券报》和 巨潮资讯网（http://w ...